New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:19 EDTQDELQuidel product launch sets up for 2015 growth, says Canaccord
Canaccord said Quidel is in the midst of a major new product launch which sets up 2015 for solid 20% growth. The firm trimmed its Q2 estimates but believes the long term thesis remains intact and keeps its Buy rating and $28 price target on Quidel.
News For QDEL From The Last 14 Days
Check below for free stories on QDEL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
09:15 EDTQDELQuidel receives FDA clearance for AmpliVue GAS Assay
Subscribe for More Information
July 25, 2014
14:51 EDTQDELQuidel management to meet with Piper Jaffray
Meeting to be held in St. Louis on July 31 hosted by Piper Jaffray.
July 23, 2014
10:02 EDTQDELOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:14 EDTQDELQuidel upgraded to Neutral from Underperform at Wedbush
Subscribe for More Information
July 22, 2014
07:08 EDTQDELLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use